CAR T-cell therapy for hard-to-treat lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 55 years old.
- You have a confirmed diagnosis of lupus with high disease activity (SLEDAI-2K score of 8 or more).
- Your lupus has not responded well to at least 6 months of standard treatments, including steroids and other medications.
- You have adequate organ function, such as healthy lungs, heart, liver, and kidneys.
- You are not pregnant or breastfeeding and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This trial tests an experimental CAR-T cell therapy (IC19) for people with systemic lupus erythematosus (SLE) that hasn't gotten better after standard treatments. The goal is to see if this therapy can safely reduce lupus disease activity.
Hear when a new Refractory Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.